Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.

MLA

Mastorino, Luca, et al. “Tildrakizumab in Real-Life Shows Good Efficacy in Moderate-to-Severe Psoriasis Regardless of Previous Use of Biologic Drugs and Joint Involvement.” Dermatologic Therapy, vol. 35, no. 11, Nov. 2022, p. e15818. EBSCOhost, https://doi.org/10.1111/dth.15818.

APA

Mastorino, L., Cariti, C., Susca, S., Sciamarrelli, N., Borriello, S., Ortoncelli, M., Stroppiana, E., Verrone, A., Dapavo, P., Quaglino, P., & Ribero, S. (2022). Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement. Dermatologic Therapy, 35(11), e15818. https://doi.org/10.1111/dth.15818

Chicago

Mastorino, Luca, Caterina Cariti, Sara Susca, Nadia Sciamarrelli, Silvia Borriello, Michela Ortoncelli, Elena Stroppiana, et al. 2022. “Tildrakizumab in Real-Life Shows Good Efficacy in Moderate-to-Severe Psoriasis Regardless of Previous Use of Biologic Drugs and Joint Involvement.” Dermatologic Therapy 35 (11): e15818. doi:10.1111/dth.15818.